Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Wird Global Tactical der nächste Highflyer im Markt für kritische Mineralien?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A402TW | ISIN: US88165K1016 | Ticker-Symbol: G28
Frankfurt
23.04.25
15:29 Uhr
0,824 Euro
+0,004
+0,49 %
1-Jahres-Chart
TEVOGEN BIO HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
TEVOGEN BIO HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,8560,93623.04.

Aktuelle News zur TEVOGEN BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.04.Tevogen Bio Holdings Inc. - 8-K, Current Report5
17.04.Tevogen Bio Inc: Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility91The agreement would facilitate providing Tevogen Bio with in-house cell therapy production capabilitiesFormalized agreement aligns with previously announced topline forecasts WARREN, N.J., April...
► Artikel lesen
15.04.Tevogen Bio Inc: Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction553WARREN, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced the commission of Databricks, Inc., a leader in data, analytics...
► Artikel lesen
09.04.Tevogen Bio Inc: Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States84WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announces its newest effort: Tevogen Generics. This effort is in response...
► Artikel lesen
09.04.Tevogen Bio Inc: Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs1
07.04.Tevogen reports high insider ownership amid market volatility1
07.04.Tevogen Bio Inc: Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission102WARREN, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), a healthcare company with dedicated efforts in immunotherapy and artificial intelligence...
► Artikel lesen
05.04.Tevogen Bio zeigt Fortschritte bei Quartalszahlen2
TEVOGEN BIO Aktie jetzt für 0€ handeln
02.04.Tevogen Bio Holdings Inc. - 10-K, Annual Report2
01.04.Tevogen Bio Holdings Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4051
26.03.Tevogen Bio Inc: Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast1
25.03.Tevogen Bio appoints new head of government affairs3
25.03.Tevogen Bio ernennt neuen Leiter für Regierungsangelegenheiten3
25.03.Tevogen Bio Inc: Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan120WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven...
► Artikel lesen
10.03.Tevogen Bio reicht Patent für T-Zell-fokussierten Impfstoff ein2
10.03.Tevogen Bio Inc: Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO200Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company's lead product candidate TVGN 489, to mitigate the risk posed by...
► Artikel lesen
08.03.Tevogen Bio Holdings Inc. (TVGN) Secures $8M Grant, Accelerates AI Initiatives with Microsoft3
07.03.Tevogen Bio Inc: Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel2
04.03.Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential-
04.03.This Tevogen Bio Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday5
Seite:  Weiter >>
87 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1